Live feed08:05:00·6hPRReleasevia QuantisnowVerrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common WartsByQuantisnow·Wall Street's wire, on your screen.VRCA· Verrica Pharmaceuticals Inc.Health Care
